Pharmaceuticals

111, Inc. Announces Second Quarter 2022 Unaudited Financial Results

SHANGHAI, Aug. 25, 2022 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced its unaudited financial results for the second quar...

2022-08-25 14:18 3957

Alpha Biopharma Announces Completion of its EVEREST Phase II/III Clinical Study of Zorifertinib in Non-Small Cell Lung Cancer Patients with Central Nervous System Metastases

* Zorifertinib is a next generation EGFR-TKI with full Blood Brain Barrier penetration targeting EGFRm+ NSCLC patients with CNS metastases * Top-line data from the study are expected around the end of 2022 SHANGHAI, Aug. 24, 2022 /PRNewswire/ -- Alpha Biopharma, a developer of innovative drugs...

2022-08-25 10:00 2381

Asieris Pharmaceuticals (688176.SH) Issued 2022 Semi-Annual Report: Accelerated Global Clinical Development and Progressive Implementation of Its Integrated Diagnosis-Treatment Commercialization Strategy

SHANGHAI,  Aug. 24, 2022 /PRNewswire/ -- Asieris Pharmaceuticals, a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, issued its 2022 semi-annual report today. As disclosed in...

2022-08-25 00:46 3416

Everest Medicines Announces Interim Results for First Half of 2022

SHANGHAI, Aug. 24, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs inAsia Pacific markets, today announced its interim r...

2022-08-24 21:10 8087

CARsgen 2022 Interim Results: Innovative CAR T-cell Technologies and Robust Pipeline

SHANGHAI, Aug. 24, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, has announced the 2022 Interim Results. Business Highlights * CT053: comple...

2022-08-24 20:50 3991

Mangosteen Peel as Medicine - CU's Faculty of Veterinary Science is Successful in Replicating Mangosteen Peel Extract, Treatment for Intestinal Inflammation in Humans and Animals

BANGKOK, Thailand, Aug. 24, 2022 /PRNewswire/ -- The Faculty of Veterinary Science,Chulalongkorn University has researched and replicated "Hydroxy- xanthones", the vital extracts rich in antioxidants found in mangosteen peels that kill germs and halt infections in the intestinal mucosa. It hopes t...

2022-08-24 10:00 3048

First US Patient Enrolled in SELUTION SLR IDE Peripheral Study

GENEVA, Switzerland, Aug. 24, 2022 /PRNewswire/ -- The first US patient has been enrolled in the FDA SELUTION4BTK (Below-the-Knee) clinical trial evaluating SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon. This milestone follows Investigational Device Exemption (IDE) approval in the ...

2022-08-24 09:00 4365

Innovent Announces First Patient Dosing in Australia in Phase 1 Study of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) in Patients with Advanced Malignancies

ROCKVILLE, Md. and SUZHOU, China, Aug. 23, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...

2022-08-24 08:00 4820

Brii Biosciences Provides Corporate Update and Reports 2022 Interim Results

Additions to executive team strengthen global leadership and position Company for strategic long-term growth First-ever product launch of long-acting amubarvimab/romlusevimab combination therapy for COVID-19 inChina advances Brii Bio from clinical development to commercial stage biotechnology co...

2022-08-24 07:30 5439

Targeted Alpha Therapy Candidate: Bladder Cancer Study Completes Enrolment

MELBOURNE, Australia and NANTES, France, Aug. 24, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and Nantes-based ATONCO S.A.S. ('ATONCO') today announced that the final patient has been dosed in a Phase I study of TLX250-CDx in patients with non-muscle invasive...

2022-08-24 05:56 4632

Jacobio Pharma Announces 2022 Interim Results

Investment in R&D increased 26.3% to RMB 221 million. Recorded revenue was RMB 54.7 million. Global development of KRAS G12C inhibitor and other clinical stage drug candidates accelerated. Development started in new pre-clinical stage drug candidates, such as iADC (immunostimulatory antibody-dr...

2022-08-24 00:32 4105

I-Mab Announces Share Purchase Plans by the Company and the Senior Management

GAITHERSBURG, Md. and SHANGHAI, Aug. 23, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it plans to implement share repurchases...

2022-08-23 21:13 4095

Zerion Pharma and Hovione extend partnership to cover use of the Dispersome® technology platform in nutraceuticals

LISBON, Portugal, Aug. 23, 2022 /PRNewswire/ -- Hovione and Zerion Pharma A/S (Zerion) today announced an extension of their collaboration on Zerion's Dispersome® technology into the nutraceutical/dietary supplements field. Many dietary supplements suffer from low solubility. This results in poor...

2022-08-23 17:58 2616

GenScript ProBio Congratulates Selecxine on FDA Clearance of IND Application for Innovative Antibody Drug Program

NANJING, China, Aug. 23, 2022 /PRNewswire/ -- Recently, Selecxine, a partner of GenScript ProBio, announces FDA clearance of its IND application for innovative antibody drug program (SLC-3010). GenScript ProBio was responsible for the CMC development and supporting IND filing in this project. Gen...

2022-08-23 14:15 3676

Announcement of 2022 Future Science Prize Winners: Wenhui Li, Xueming Yang, Ngaiming Mok

BEIJING, Aug. 23, 2022 /PRNewswire/ -- The Future Science Prize committee announces the winners of 2022 onAugust 21st. Prof. Wenhui Li from National Institute of Biological Sciences,Beijing, China; Tsinghua Institute of Multidisciplinary Biomedical Research receives the Future Science Prize in li...

2022-08-23 11:52 3754

Brii Biosciences Appoints Eleanor de Groot as Chief Technology Officer and Aleksandar Skuban as Central Nervous System Diseases Therapy Area Head

Building a leadership team with global and local experience and expertise to enable rapid execution across Company's broad therapeutic strategy DURHAM, N.C. and BEIJING, Aug. 23, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock ...

2022-08-23 07:30 5091

AVELOS THERAPEUTICS ANNOUNCES $8 MILLON SERIES A FUNDING ROUND

Seoul-Based Biotechnology Company to Use Financing for Expanding Oncology Drug Discovery and Development SEOUL, South Korea, Aug. 22, 2022 /PRNewswire/ -- Innovative biotechnology company specializing in new drug discovery and development, Avelos Therapeutics, has received a glowing endorsement ...

2022-08-22 20:00 2632

LTS takes next step in its Growth Journey with the acquisition of Tapemark Inc.

ANDERNACH, Germany, Aug. 22, 2022 /PRNewswire/ -- LTS LOHMANN Therapie-Systeme AG ("LTS") announces the closing of the acquisition of Tapemark Inc. ("Tapemark") located inSt. Paul, MN, USA. This acquisition combines Tapemark, a world-class CDMO specialized in transdermal drug delivery systems and...

2022-08-22 18:00 2267

The 2022 Smart China Expo kicked off, smart technology empowers Chongqing Liangjiang New Area to lead innovative development

CHONGQING, China, Aug. 22, 2022 /PRNewswire/ -- The 2022 Smart China Expo will be held in Liangjiang New Area of southwest China'sChongqing from August 22 to 24, with the theme of "Smart Technology: Empowering Economy, Enriching Life". As the most influential event in China's intelligent industry...

2022-08-22 15:37 5892

Biosion, Inc. Appoints Steven Knapp, Pharm.D. as Chief Regulatory & Quality Officer

NEWARK, Del. and NANJING, China, Aug. 22, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a leading global R&D biotechnology company, today announced the appointment ofSteven Knapp, PharmD., as Chief Regulatory & Quality Officer. In this position, he is responsible for the strategic leadership...

2022-08-22 13:00 2362
1 ... 287288289290291292293 ... 351